French pharmaceutical maker Sanofi will reduce the US list price of Lantus, its most-prescribed insulin, by 78%, according to a statement Thursday. The company will also reduce the list price of Apidra by 70%.
“We are pleased to see others join our efforts to help patients as we now accelerate the transformation of the US insulin market,” said Olivier Bogillot, the head of US general medicines. “Our decision to cut the list price of ...